RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin

Journal of Biomedical Materials Research - Part A

Volumn 80, Issue 1, 2007, Pages 75-84

  Garcia Filipe, S ^a   Barbier Chassefiere, V ^b   Alexakis, C ^a   Huet, E ^a   Ledoux, D ^a   Kerros, M E ^a   Petit, E ^b   Barritault, D ^b   Caruelle, J P ^a   Kern, P ^a  

^a Université de Paris 12 Val de Marne ^*  (France)

^b OTR3 SAS   (France)

Author keywords

Burn; Collagens; Heparan mimetic; Metalloproteinases; RGTA; Skin fibrosis

Indexed keywords

BIOMEDICAL ENGINEERING; COLLAGEN; PATIENT TREATMENT; SKIN; TISSUE;

HEPARAN-MIMETIC; METALLOPROTEINASES; RGTA; SKIN FIBROSIS;

BIOMIMETIC MATERIALS;

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5; GELATINASE A; GELATINASE B; HEPARAN SULFATE; OTR 4120; REGENERATING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURN; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST CULTURE; IN VITRO STUDY; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SKIN FIBROBLAST; SKIN FIBROSIS; TREATMENT DURATION; WOUND HEALING;

ANIMALS; BIOMIMETIC MATERIALS; BURNS; CICATRIX; FIBRILLAR COLLAGENS; HEPARITIN SULFATE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RATS; RATS, NUDE; SKIN; TIME FACTORS; WOUND HEALING;

EID: 33845485024     PISSN: 00219304     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.30874     Document Type: Article

References (44)

1. Jackson DS. Development of fibrosis: Cell proliferation and collagen biosynthesis. Ann Rheum Dis 1977;36:2-8.
2. Rockwell WB, Cohe IK, Ehrlich HP. Keloids and hypertrophic scars: A comprehensive review. Plast Reconstr Surg 1989;84:827-837.
3. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: From wound healing to fibrosis. Int J Biochem Cell Biol 1997;29:5-17.
4. Liu B, Connolly MK. Type III and I procollagen markers in fibrosing alveolitis. Am J Respir Crit Care Med 1999;159:818-823.
5. Tuan TL, Nichter LS. The molecular basis of keloids and hypertrophic scar formation. Mol Med Today 1998;4:19-24.
6. Rumalla VK, Borah GL. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg 2001;108:719-733.
7. Stallmach A, Schuppan D, Riese HH, Matthes H, Riecken EO. Increased collagen III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease. Gastroenterology 1992;102:1920-1929.
8. Pucilowska JB, William KL, Lund PK. Fibrogenesis IV. Fibrosis and inflammatory bowel disease: Cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-G659.
9. Ullrich D, Noah EM, Burchardt ER, Atkins D, Palua N. Serum concentration of amino-terminal propeptide of type III procollagen (PIIINP) as a prognostic marker for skin fibrosis after scar correction in burned patients. Burns 2002;28:766-771.
10. Ullrich D, Noah EM, von Heimbur D, Palua N. TIMP-1, MMP-2, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast Reconstr Surg 2003;111:1423-1431.
11. Jensen LT. The amino-terminal propeptide of type III procollagen: Studies on physiology and pathophysiology. Dan Med Bull 1997;44:70-78.
12. Zachariae H, Heickendorff LL, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: A 10-year follow-up. Br J Dermatol 2001;144:100-103.
13. Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with Regenerating Agents. Gut 2004;53:86-91.
14. Saliba MJ Jr. Heparin in the treatment of burns: A review. Burns 2001;27:349-358.
15. Song YK, Kim CK. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 2001;27:271-280.
16. Asselot-Chapel C, Combacau L, Labat-Robert J, Kern P. Expression of fibronectin and interstitial collagen genes in smooth muscle cells: Modulation by low molecular weight heparin fragments and serum. Biochem Pharmacol 1995;49:653-659.
17. Alexakis C, Mestries P, Garcia S, Petit E, Barbier V, Papy-Garcia D, Sagot MA, Barritault D, Caruelle JP, Kern P. Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth Factor-β1. FASEB J 2004;18:1147-1149.
18. Alexakis C, Guettoufi A, Mestries P, Duchesnay A, Barritault D, Caruelle JP, Kern P. Heparan mimetic regulates collagen expression and TGF-β1 distribution in γ-irradiated human intestinal smooth muscle cells. FASEB J 2001;15:1546-1554.
19. Mestries P, Borchiellini C, Barbaud C, Duchesnay A, Escartin Q, Barritault D, Caruelle JP, Kern P. Chemically modified dextrans modulate expression of collagen phenotype by cultured smooth muscle cells in relation to the degree of carboxy-methyl, benzylamide and sulfation substitutions. J Biomed Mater Res 1998;42:286-294.
20. Meddahi A, Benoit J, Ayoub N, Sezeur A, Barritault D. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J Biomed Mater Res 1996;31:293-297.
21. Ledoux D, Papy D, Escartin Q, Sagot MA, Cao Y, Barritault D, Courtois J, Hornebeck, Caruelle JP. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J Biol Chem 2000;275:29383-29390.
22. Morvan FO, Baroukh B, Ledoux D, Caruelle JP, Barritault D, Godeau G, Saffar JL. An engineered biopolymer prevents mucositis induced by 5-fluorouacil in hamsters. Am J Pathol 2004;164:739-746.
23. Papy-Garcia D, Barbier-Chassefière V, Rouet V, Kerros ME, Klochendler C, Tournaire MC, Barritault D, Caruelle JP, Petit E. Non degradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005;38:4647-4654.
24. El Nabout R, Martin M, Remy J, Kern P, Robert L, Lafuma C. Collagen synthesis and deposition in cultured fibroblasts from subcutaneous radiation-induced fibrosis. Modification as a function of cell aging. Matrix 1989;9:411-420.
25. Kern P, Menasche M, Robert L. Relative rates of biosynthesis of collagen type I, type V and type VI in calf cornea. Biochem J 1991;274:615-617.
26. Okada A, Santaviccca M, Basset P. The cDNA cloning and expression of gene encoding rat gelatinase B. Gene 1995;164:317-321.
27. Crabbe T, Ioannou C, Docherty AJ. Human progelatinase A can be activated by autolysis at a rate that is concentration-dependent and enhanced by heparin bound to the C-terminal domain. Eur J Biochem 1993;218:431-438.
28. Nagase H, Suzuki K, Morodomi T, Enghild JJ, Salvesen G. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2 and 3. Matrix Suppl 1992;1:237-244.
29. Yu WH, Woessner JF Jr. Heparin-enhanced zymographic detection of matrilysin and collagenases. Anal Biochem 2001;293:38-42.
30. Scott PG, Dodd CM, Tredge EE, Ghahary RF. Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scar. Clin Sci 1996;90:417-425.
31. Jabr K, Jonhson JH, McDonald MH. Plasma modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin induced thrombocytopenia. J Extra Corpor Technol 2004;36:174-177.
32. Mestries P, Alexakis C, Papy-Garcia D, Duchesnay A, Barritault D, Caruelle JP, Kern P. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-β1. Matrix Biol 2001;20:171-181.
33. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators and protectors of acidic or basic FGF. J Cell Physiol 1992;150:194-203.
34. Young PK, Grinell F. Metalloproteinase activation cascade after burn injury: A longitudinal analysis of the human wound environment. J Invest Dermatol 1994;103:660-664.
35. Lee YJ, Shin KC, Kang SW, Lee E, Kim HA, Song YW. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, von Willebrand factor in systemic sclerosis. Clin Exp Rheumatol 2001;19:69-74.
36. Lammi L, Ryhanen L, Lakari E, Risteli J, Paako P, Ruotsalainen EM, Lahde S, Kinnula VL. Type III and I procollagen markers in fibrosis alveolitis. Am J Resp Crit Care Med 1999;159:818-823.
37. Weigand K, Zaug PY, Frei A, Zimmerman A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835-838.
38. Sawicki G, Marcoux Y, Sarkhosh K, Tredget EE, Gahahary A. Interaction of keratinocytes and fibroblasts modulates the expression of matrix mettaloproteinases-2 and -9 and their inhibitos. Mol Cell Biochem 2005;269:209-216.
39. + for fibronectin and heparin binding. Binding properties of recombinant gelatinase A C domain to extracellular matrix and basement membrane components. J Biol Chem 1997;272:7473-7481.
40. Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in culture. Int Rev Cytol 1996;169:183-265.
41. Seomun Y, Kim JA, Lee EH, Joo CK. Over-expression of matrix metalloproteinase-2 mediates phenotypic transformation of lens epithelial cells. Biochem J 2001;258:41-48.
42. Fan WH, Karnovsky MJ. Increased MMP-2 expression in connective tissue growth factor over-expression vascular smooth muscle cells. J Biol Chem 2002;277:9800-9805.
43. Han HP, Tuan TL, Hughes M, Wu H, Garner W. Transforming growth factor β and tumor necrosis factor α-mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 2000;276:22341-22350.
44. Vlodavski I, Friedman Y, Elkin M, Aingorn H, Atzmon R, Ishai-Micheli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 1999;5:793-802.